AnaptysBio, Inc.’s Imsidolimab Performs Well in Phase 3 GPP Study

May 9, 2024

LEO’s Enstilar Performs Well in Phase 3 Study of Adults With Stable Plaque Psoriasis in China

May 7, 2024

Major Step Forward: FDA Clears IND Application for Vyne’s BD2-Selective BET Inhibitor

May 7, 2024

Dr. Stefan C. Weiss Joins SFA Therapeutics as Chief Medical Officer

May 2, 2024

Biosimilar News: FDA Approves High-concentration, Citrate-free Formulation of Cyltezo, a Biosimilar to Humira

May 1, 2024

Biosimilar News: Two Approvals in Europe, Celltrion USA Signs Agreement with Express Scripts

April 29, 2024

Changing Paradigms in the Topical Treatment of Psoriasis

April 29, 2024

FDA Accepts UCB’s sBLA for 2 mL Bimzelx Device

April 22, 2024

EC Gives Nod to Ustekinumab Biosimilar

April 22, 2024

FDA Green Lights New Stelara Biosimilar

April 16, 2024

Paragon Therapeutics’ Oruka Merges With ARCA to Advance Novel Treatments for PsO, PsA

April 3, 2024

Rodney Cotton Joins Castle Biosciences’ Board of Directors

March 28, 2024